Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting Phase 1 Trials for Pyrvinium (DB06816)
Also known as: Resectable Pancreatic Ductal Adenocarcinoma
| Indication | Status | Phase |
|---|---|---|
| DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC)) | Recruiting | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT05055323 | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer | Treatment |